What the pCPA's GLP-1 decision really signals for specialty distribution
The headline is the negotiated price. The story is who controls the channel — and this week the pan-Canadian Pharmaceutical Alliance quietly redrew the map for everyone holding inventory.
PMPRB's retreat on the new guidelines is a win pharma won't celebrate out loud
Dropping the contentious price tests looks like an industry victory. The second-order effect on launch sequencing is the part worth watching.
CADTH / INESSSCADTH's conditional recommendation isn't about the drug. It's a message to the provinces.
Read the reimbursement conditions as an opening negotiating position, not a clinical verdict — and watch who blinks first.
BiosimilarsHealth Canada's biosimilar NOC starts a clock the originator can't stop
Notice of Compliance is the starting gun, not the finish line. Here's how the next 18 months of switching policy likely plays out.
The news is the commodity. The read is the product.
Read every analysis free with an account, ad-supported on the web. The Connector brings that same interpretation — structured, queryable, with the full archive — into your own AI assistant.